 SHELTON, CT ACCESSWIRE July 9, 2020 NanoViricides, Inc. NYSE American:NNVC the Company a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform the Company, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately 10.0 million before deducting underwriting discounts and other estimated offering expenses. The proposed offering equates to 1,369,863 million shares of the Companys common stock at a price of 7.30 per share. The Company intends to use the net proceeds from this offering for general corporate purposes and to fund ongoing operations. 